• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Product, or active agent, or composition for the care of the breasts in premenstrual or menstrual period or for the care of the symptomatology of mastodynia. The invention relates to a product, either an active agent, or a composition. This product, active agent or composition consists essentially of peroxidized lipids, such as for example peroxidized glycerol triesters (abbreviation TGO) in particular in the form of peroxidized vegetable oil, for the care or treatment of the breasts during the premenstrual or menstrual phases and also for the treatment of symptomatology of mastodynia. The invention allows the implementation of a method of care or treatment of the sinuses during the premenstrual or menstrual phases as well as the care or treatment of the symptomatology of mastodynia. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2657828A2
    申请号:ES201730858
    申请日:2017-06-28
    公开日:2018-03-07
    发明作者:Stéphane Desjonqueres
    申请人:Laboratoires Carilene；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5
    image6
    image7
    image8


    b2) antimicrobial agent 1% approximately
    for example MICROCARE® PHC ...
    b3) texture agent or thickener, 1% approximately
    for example ARISTOFLEX® AVC
    b4) possibly a perfume or a mixture of perfumes to improve the smell approximately 1% For example: cornflower-based perfume 0.50% white lotus perfume 0.40% b5) of mineralized water of cosmetic or pharmaceutical quality, such as solution that allows to perform the emulsion, QSP 100%.
    The preparation of this emulsion is carried out in a classical manner, as indicated in example 1.
    The mixing of the ingredients is carried out as in the context of example 1 in order to obtain an emulsion-shaped composition with a consistency of a cream called RD6.
    This composition is the subject of the following clinical study indicated in Example 4. Example 3 of the invention Topical allantoin product or composition
    This product or topical composition to allantoin, for clinical study includes the following composition, in% by weight:
    a) peroxidized glycerol tri esters obtained from peroxidized corn oil, with a degree of peroxidation between 5 and 600 milliequivalents per kg 50% approximately
    b) approximately 0.5% allantoin excipient c) other active agents or excipients c1) approximately 2% emulsifying and solubilizing mixing agent for example LRI® solubilizer c2) approximately 1% antimicrobial agent for example MICROCARE® PHC
    10
    image9
    image10
    image11
    image12
    image13


    3) During the third consultation (C2) performed optimally after three treatment cycles: -the pain was measured with a mean of 2.19 with extremes of 0 to 0.875: 1.96 for hospital patients and 2.48 for the client of the private consultation. The improvement of the patients evolved between the second consultation (C1) and the third consultation (C2) at 29%, that is, 50% in the hospital setting, but no improvement has been noted in the framework of the private consultation. -The tension was measured at, 68 with extremes ranging from 0 to 5: 1.56 for the hospital versus 1.84 for the liberal cabinet. Here too, the improvement was 47% with respect to consultations (C1), 59% in the hospital compared to 21% in private practice. -the heaviness with a measure of 1.75 on average with extremes between 0 and 5.28: 1.67 for the hospital versus 1.84 for private consultation. The improvement between C1 and C2 has reached 38%: 54% of the clientele of a hospital compared to 5% of the clientele of private practice. In total, between the first inclusion consultation (C0) and the last consultation (C2) corresponding to an optimal 3-cycle treatment, the improvement is notable: -for pain in 63% of cases, 68% in hospital and 57 % in liberal, -for tension in 71% of cases, 79% in hospital and 53% in private practice, -for tension in 71% of cases, 79% in hospital and 53% in private practice, - for heaviness in 69% of cases, 76% in hospital and 56% in private practice.
    E) OBJECTIVE CLINICAL EVALUATION 1) The weight
    The variation of the patients during the study was of little importance: -in C0 = 57.4 kg (with extremes ranging from 49 to 71 kg) -in C1 = 57.3 kg -in C2: = 57.2 kg
    Between C0 and C2, an average distance of 0.247 g can be seen with ends of -3.5 kg and
    + 5 kg corresponding for patients during holiday periods. Only 10 patients saw their weight decrease during the study, that is 10 out of 34 = 29.4%
    -0.5 kg for 2 patients -1 kg for 6 patients
    16
    image14
    image15
    image16


    Between C0 and C1, it is noted: -a good improvement in 66.67% of cases -a very good in 27.77% of cases. This causes an overall improvement of 17 patients over 18.
    In total between C0 and C2, there is a 100% improvement in 33% of patients, with good results and in 67% of patients, with very good results. 5.6 -The presence of maxillary nodes
    The presence of axial nodes is a reflection of the state of breast inflammation.
    This sign has been found in 13 patients, which corresponds to 38.24% of the
    patients -in C1: 9 patients still presented axillary lymphadenopathy -in C2: 7 (20.59%) this allows us to find an improvement of this
    symptom in 4 patients over 12.
    In total, the improvement between C0 and C2 has been noted in 8 patients celebrated over 13. 6) The cosmetic evaluation of the product
    The analysis of the assessment, by the patients of the cosmological qualities of the product of Example 2, is quite harmonious since: -the texture is very pleasant or pleasant for 23 patients with a notion of rapidly obtained freshness and softness in the skin after penetration of the product. -Easy application is seen in 93.93% of patients.
    The only restrictions affect: -the qualified smell of "fries" or "butter" by 54% of women -the presentation by boat (tendency to disappear under the effect of heat).
    In total: subject to a modification of the presentation (dosed bottle for example) and the smell, the product of example 2 is a very well perceived product thanks
    twenty


    to its fluid texture that penetrates quickly, the simple and fast and efficient application: 84.85% of the patients are willing to continue with the treatment. III) THE DISCUSSION
    This study of the product of the invention affects 34 patients. Very few patients left the trial for reasons linked to the product: one for allergy but the patient had a known history, another for smell intolerance while it was effective and in reality only two (2/34: 5.8%) for lack of efficacy .
    A better observance of the term of the different consultations is observed in the Hospital given the recruitment that involves the female medical population widely
    or paramedic of the Hospital outside the particular moment of the holidays where the extremes could be observed.
    The age of the disorders is an unreliable fact since it is a notion based solely on the memory of patients.
    The group of patients who consulted in the hospital presents an associated pathology more frequently; This is directly linked to the very surgical recruitment of the hospital consultation and to the longer term of the consultation itself, selecting thanks to the patients who present more pronounced pathologies with the presence of associated organic signs.
    During the inclusion house this was clearly evidenced in the analogue scales of breast tension (7.22 vs. 3.95) and heaviness (6.83 vs. 4.14).
    From the first month of treatment the decrease in pain is better and faster in private practice (60% improvement compared to 37%).
    This highlights the speed of the effectiveness of the product in pain; This speed could be linked to a better observation of patients in private practice with a more regular application, but it is also in this population that a more moderate intensity of painful symptomatology in inclusion is observed.
    twenty-one
    image17
    image18
    image19
    image20
    权利要求:
    Claims (1)
    [1]
    image 1
    image2
    image3
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2675045T3|2018-07-06|Synergistic active preparations comprising 1,2-decanediol and also antimicrobial active compounds
    ES2301189T3|2008-06-16|ANTIMICROBIAL CLEANING AGENTS.
    Khatri et al.2015|Evaluation of effect of topical ozone therapy on salivary Candidal carriage in oral candidiasis
    Verma et al.2014|The antimicrobial effectiveness of 25% propolis extract in root canal irrigation of primary teeth
    Cunha et al.2020|Cytotoxicity and antimicrobial effects of citronella oil | and commercial mouthwashes on S. aureus and C. albicans biofilms in prosthetic materials
    Poorni et al.2009|Comparative evaluation of the surface tension and the pH of calcium hydroxide mixed with five different vehicles: An in vitro study
    JPWO2006115190A1|2008-12-18|Skin cosmetics and wrinkle improvers
    ES2657828A2|2018-03-07|PRODUCT, OR ACTIVE AGENT, OR COMPOSITION FOR THE CARE OF THE BREASTS IN PRE-MENSTRUAL OR MENSTRUAL PERIOD OR FOR THE CARE OF THE SYMPTOMATOLOGY OF THE MASTODINIAS |
    JP2007217394A|2007-08-30|Pharmaceutical composition
    Prasad et al.2016|Evaluation of antimicrobial efficacy of neem and Aloe vera leaf extracts in comparison with 3% sodium hypochlorite and 2% chlorhexidine against E. faecalis and C. albicans
    BR112016021994B1|2020-12-08|formulation for personal hygiene
    ES2379474T3|2012-04-26|Dermatological product for the treatment and / or skin care with neurodermitis
    ES2803924T3|2021-02-01|Composition for topical application with antifungal activity
    Wimardhani et al.2014|Oral mucosal ulceration caused by the topical application of a concentrated propolis extract
    BE1025392B1|2019-03-29|OCTENIDINE HYDROCHLORIDE CONTAINING EMULSIONS
    ES2601249B1|2017-11-22|PROCESS OF ELABORATION OF SANITARY CREAM AND RESULTING PRODUCT
    ES2333641T3|2010-02-25|USE OF PEROXIDATED LIPIDS TO PREVENT AND / OR TREAT IRRITANT EFFECTS OF AN ACTIVE PRINCIPLE.
    Akash et al.2021|Role of Hand Sanitizers in Infection Control Practices
    JP6741433B2|2020-08-19|Emulsion composition for disinfection
    ES2853734T3|2021-09-17|Salt-based gel and its use in the prevention and treatment of parasitosis and dermatological conditions
    WO2014186603A1|2014-11-20|Compositions for improving the hair, skin, and nails
    ES2333574A1|2010-02-23|Composite for the treatment of skin irritations |
    ES2211341B1|2005-05-16|COMPOSITIONS CONTAINING OZONIZED NATURAL OILS.
    Anas et al.2021|Effectiveness Of Paste Based Moringa Oleifera To Increase Calcium Levels Human Tooth |
    BR102015013231B1|2021-03-23|PREPARATION OF MICROEMULSION DEVELOPED BASED ON COPAÍBA OIL FOR DENTAL USE
    同族专利:
    公开号 | 公开日
    ES2657828R1|2018-05-17|
    GB201710439D0|2017-08-16|
    FR3053252B1|2020-04-24|
    US20180002281A1|2018-01-04|
    ES2657828B2|2019-03-13|
    GB2556959A|2018-06-13|
    FR3053252A1|2018-01-05|
    DE102017114413A1|2018-01-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0707850A1|1994-09-21|1996-04-24|Scotia Holdings Plc|Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain|
    MY118354A|1995-05-01|2004-10-30|Scarista Ltd|1,3-propane diol derivatives as bioactive compounds|
    FR2793410B1|1999-05-12|2004-10-29|Carilene Lab|USE OF PEROXIDE LIPIDS AS AGENTS FOR PREVENTING AND / OR TREATING THE IRRITATING EFFECTS OF AN ACTIVE INGREDIENT|
    FR2797586B1|1999-08-16|2001-11-09|Stephane Desjonqueres|USE OF PEROXIDE LIPIDS AS AGENTS FOR FORMING LIPID FILM ON THE SKIN|
    US20040081672A1|2002-10-25|2004-04-29|Gupta Shyam K.|Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging|
    FR2848852B1|2002-12-23|2007-03-16|Carilene Lab|OILY COMPOSITION BASED ON PEROXIDIC LIPIDS USEFUL IN THE TREATMENT OF XEROSTOMY|
    US20090130048A1|2007-11-19|2009-05-21|Oronsky Bryan Todd|Topical Composition for Treating Pain|
    FR2929516A1|2008-04-03|2009-10-09|Carilene Lab|DERMATOLOGICAL COMPOSITION USED IN PARTICULAR FOR THE CARE AND PREVENTION OF THE ESCARRES|
    EP2355903A1|2008-06-19|2011-08-17|Lina Kennedy|Product and composition for alleviating post-menstrual symptoms comprising carapa procera and calotropis procera|
    FR2947178B1|2009-06-29|2012-07-06|Effik|PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF|
    FR2954701B1|2009-12-24|2012-02-03|Carilene Lab|DERMATOLOGICAL COMPOSITIONS COMPRISING AN ASSOCIATION OF PEROXIDE LIPIDS AND ZINC AND THEIR USES IN PARTICULAR IN THE TREATMENT OF HERPES|
    US20130345316A1|2012-06-21|2013-12-26|L'oreal|Water-releasing cosmetic composition|
    法律状态:
    2019-03-13| FG2A| Definitive protection|Ref document number: 2657828 Country of ref document: ES Kind code of ref document: B2 Effective date: 20190313 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1656119|2016-06-29|
    FR1656119A|FR3053252B1|2016-06-29|2016-06-29|PRODUCT, OR ACTIVE AGENT, OR COMPOSITION FOR THE CARE OF THE BREAST IN THE PRE-MONTHLY OR MENSTRUAL PERIOD OR FOR THE CARE OF THE SYMPTOMATOLOGY OF MASTODYNIA|
    [返回顶部]